The general course of interferon for hepatitis B patients is one year, but in clinical practice the response to interferon treatment varies greatly from patient to patient, so we have to look at it while treating, and generally evaluate it once every three months and once every six months. If the patient has a good treatment effect and there are no obvious side effects or tolerable side effects, we will continue the treatment. If the treatment is not effective, for example, the decrease in hepatitis B virus DNA during the treatment is not significant, the decrease in hepatitis B e antigen and surface antigen does not reach our expected effect, and the treatment is not predicted to be effective, then we should consider discontinuing interferon and switching to nucleoside antiviral drugs. If the treatment effect is good and the decrease in e antigen and surface antigen is large at one year of treatment, it may be necessary to continue to extend the course of treatment and use interferon again, so that the course of treatment reaches one and a half or two years to achieve better treatment goals.